We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo

By LabMedica International staff writers
Posted on 21 May 2026

In eastern Democratic Republic of the Congo, communities are confronting a resurgence of Bundibugyo ebolavirus, a rarer species for which no vaccines or treatments have been approved. More...

Ebola is a highly contagious virus that spreads through bodily fluids such as blood, vomit, or semen, and the disease it causes is rare but severe and often fatal. Symptoms can include fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising.

Limited laboratory capacity and long sample transport routes have complicated diagnosis, while health authorities have reported that early misdirected testing and limited access to Bundibugyo-specific assays contributed to delayed detection.

The World Health Organization (WHO) has expressed concern over the “scale and speed” of the outbreak, which involves more than 500 suspected cases and 134 suspected deaths. Confirmed cases include 30 in Congo and two in Uganda, including one death. WHO has declared a public health emergency of international concern, citing urban transmission, deaths among healthcare workers, and population movement as factors compounding the risk. Confirmed cases have been reported in Bunia, Goma, Mongbwalu, Nyakunde, and Butembo.

Laboratory confirmation for Bundibugyo ebolavirus currently depends on centralized testing capacity in Kinshasa and Goma. Early samples from Bunia were tested only for the more common Zaire ebolavirus and returned negative results, allowing transmission to continue undetected for weeks. Authorities have also noted that no approved medicines or vaccines are available for the Bundibugyo species.

The outbreak chronology highlights the diagnostic gap. The first known death occurred on April 24 in Bunia, but confirmation did not come for weeks. After a subsequent illness on April 26, samples were sent to Kinshasa, more than 1,000 kilometers from Bunia. WHO was alerted on May 5 to approximately 50 deaths in Mongbwalu, and the first laboratory confirmation followed on May 14.

The current response is also shaped by lessons from past Ebola outbreaks. During the West African outbreak more than a decade ago, which killed more than 11,000 people, many infections occurred during funeral practices, including washing the bodies of those who had died. Such risks underscore the importance of rapid detection, infection-control measures, safe burials, and community engagement.

Response operations continue to expand. WHO indicated that any approved vaccine option considered for use would take approximately two months to become available, while shipments of experimental vaccines targeting other Ebola types are expected from the United States and Britain. On the ground, Doctors Without Borders and the Red Cross are supporting response efforts, UNICEF has delivered 16 tons of supplies for three treatment centers in Ituri province, and authorities are working to break chains of transmission.

Related Links
World Health Organization


New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
Repetitive Pipette
VWR® Stepper Pro
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image Credit: Adobe Stock

New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients

Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.